
    
      The purpose of this study is to evaluate the efficacy and safety of umbralisib monotherapy
      and the umbralisib + ublituximab (U2) combination in aggressive and indolent lymphomas and to
      also explore the U2 regimen in combination with bendamustine in the treatment of NHL (FL,
      SLL, MZL, DLBCL and MCL).
    
  